As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib
Joint Authors
Liu, Lei
Wang, Enxin
Li, Lin
Chen, Dongyu
Peng, Kun
Wang, Mengmeng
Han, Guohong
Source
Canadian Journal of Gastroenterology and Hepatology
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-11-14
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Background.
Combination therapy of transarterial chemoembolization plus sorafenib (TACE-S) has been proven to be safe and effective for hepatocellular carcinoma (HCC); however, this combination therapy is associated with a high incidence of adverse events (AEs).
Our study focused on the relationships between AEs and treatment outcomes and aimed to discover AE-based clinical markers that can predict the survival benefits of combination treatment.
Methods.
From January 2010 to June 2014, a total of 235 HCC patients treated with TACE-S were retrospectively enrolled.
Major sorafenib-related AEs were prospectively recorded, and their correlations with overall survival (OS) were analysed using time-dependent covariate Cox regression analyses.
Results.
The majority of the patients (200, 85.1%) were male, and the median age was 51 years old.
After two years of follow-up, the median OS of the study population reached 12.4 months.
In all, 218 patients (92.8%) presented at least one AE, and 174 (74.0%) suffered AEs ≥2 grade.
Based on time-dependent multivariate analyses, the development of hand-foot skin reaction (HFSR) ≥2 grade (HR = 0.43, 95% CI: 0.32–0.58, P<0.001) and diarrhoea ≥1 grade (HR = 0.72, 95% CI: 0.53–0.97, P=0.029) were identified as independent predictors of prolonged OS.
Moreover, patients who developed both HFSR ≥2 grade and diarrhoea ≥1 grade achieved better outcomes than those patients who developed either or neither of these AEs (HR = 1.51, 95% CI: 1.11–2.06, P=0.009).
Conclusions.
The development of HFSR ≥2 grade or diarrhoea ≥1 grade during TACE-S treatment indicated prolonged OS, and these AEs should be considered important clinical markers for predicting patient prognoses.
American Psychological Association (APA)
Liu, Lei& Wang, Enxin& Li, Lin& Chen, Dongyu& Peng, Kun& Wang, Mengmeng…[et al.]. 2019. As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib. Canadian Journal of Gastroenterology and Hepatology،Vol. 2019, no. 2019, pp.1-7.
https://search.emarefa.net/detail/BIM-1129796
Modern Language Association (MLA)
Liu, Lei…[et al.]. As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib. Canadian Journal of Gastroenterology and Hepatology No. 2019 (2019), pp.1-7.
https://search.emarefa.net/detail/BIM-1129796
American Medical Association (AMA)
Liu, Lei& Wang, Enxin& Li, Lin& Chen, Dongyu& Peng, Kun& Wang, Mengmeng…[et al.]. As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib. Canadian Journal of Gastroenterology and Hepatology. 2019. Vol. 2019, no. 2019, pp.1-7.
https://search.emarefa.net/detail/BIM-1129796
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1129796